Vera Therapeutics VERA Accretion Of Discount And Amortization Of Premium On Purchase Of Debt Securities
Accretion Of Discount And Amortization Of Premium On Purchase Of Debt Securities at other companies
Other financials
Where this comes from
Reported directly by Vera Therapeutics in its filing.
Tagged under the XBRL concept vera:AccretionOfDiscountAndAmortizationOfPremiumOnPurchaseOfDebtSecurities.
The official record: Vera Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vera Therapeutics's accretion of discount and amortization of premium on purchase of debt securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vera Therapeutics's accretion of discount and amortization of premium on purchase of debt securities?
- Vera Therapeutics (VERA) reported accretion of discount and amortization of premium on purchase of debt securities of -$843K in Q1 2026.
- How has Vera Therapeutics's accretion of discount and amortization of premium on purchase of debt securities changed year-over-year?
- Vera Therapeutics's accretion of discount and amortization of premium on purchase of debt securities increased by 66.7% year-over-year, from -$2.53M to -$843K.
- What does accretion of discount and amortization of premium on purchase of debt securities mean?
- This represents the non-cash adjustment to net income resulting from the amortization of premiums or accretion of discounts on debt securities held as investments. It reflects the gradual adjustment of the carrying value of debt instruments toward their par value over time. This metric is essential for reconciling net income with actual cash flows from operating activities.